Nasdaq · CIK 0001850902
TKNO Alpha Teknova, Inc.
Insider trading from SEC Form 4. Last filing Mar 9, 2026. Close $8.84 on Oct 9, 2026, +344% from the 52-week low and -5% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
TKNOOct 9, 2026 · close 8.84
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Alpha Teknova, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | Matthew Lowell Chief Financial Officer buy | $88k 40,000 shares | +31% | +6% from low-70% from high | |
| 61Notable | Stephen Gunstream President and CEO buy | $56k 26,000 shares | +11% | +6% from low-70% from high | |
| 11Weak | Martha J Demski director sell | $41k 8,000 shares | -40% | - |
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | Matthew Lowell Chief Financial Officer | POpen-market purchase Common Stock | +40,000 | $2.19 | $88k | 168,376 | Mar 9, 2026 |
| Mar 6, 2026 | Stephen Gunstream President and CEO | POpen-market purchase Common Stock | +26,000 | $2.15 | $56k | 269,497 | Mar 9, 2026 |
| Feb 15, 2026 | Damon Terrill General Counsel and CCO | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +148,000 | $0.00 | $0 | 148,000 | Mar 9, 2026 |
| Feb 15, 2026 | Matthew Lowell Chief Financial Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +171,000 | $0.00 | $0 | 171,000 | Mar 9, 2026 |
| Feb 15, 2026 | Stephen Gunstream President and CEO | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +429,000 | $0.00 | $0 | 429,000 | Mar 9, 2026 |
| Jun 27, 2025 | Martha J Demski director | SOpen-market sale Common Stock10b5-1 | -8,000 | $5.06 | $41k | 12,000 | Jul 1, 2025 |
| Jun 17, 2025 | Martha J Demski director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +54,300 | $0.00 | $0 | 54,300 | Jul 1, 2025 |
| Jun 17, 2025 | Brett Robertson director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +54,300 | $0.00 | $0 | 54,300 | Jul 1, 2025 |
| Jun 17, 2025 | Alexander Vos director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +54,300 | $0.00 | $0 | 54,300 | Jul 1, 2025 |
| Jun 17, 2025 | Martha J Demski director | AGrant or award Common Stock | +54,300 | $0.00 | $0 | 74,300 | Jun 25, 2025 |
| Jun 17, 2025 | Brett Robertson director | AGrant or award Common Stock | +54,300 | $0.00 | $0 | 102,472 | Jun 25, 2025 |
| Jun 17, 2025 | Alexander Vos director | AGrant or award Common Stock | +54,300 | $0.00 | $0 | 102,472 | Jun 25, 2025 |
| Feb 14, 2025 | Stephen Gunstream President and CEO | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +393,663 | $0.00 | $0 | 393,663 | Jun 25, 2025 |
| Feb 14, 2025 | Matthew Lowell Chief Financial Officer | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +169,857 | $0.00 | $0 | 169,857 | Jun 25, 2025 |
| Feb 14, 2025 | Damon Terrill General Counsel and CCO | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +137,808 | $0.00 | $0 | 137,808 | Jun 25, 2025 |
| Feb 27, 2025 | Brett Robertson director | JOther Common Stockindirect: by Trust | +5,000 | $0.00 | $0 | 5,000 | Feb 27, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Martha J Demskidirector
- Stephen GunstreamPresident and CEO
- Matthew LowellChief Financial Officer
- Brett Robertsondirector
- Damon TerrillGeneral Counsel and CCO
- Alexander Vosdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.